Nature Communications (Apr 2021)
Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia
Abstract
Lipocalin 2 (LCN2) has been recently identified as an endogenous regulator of appetite. Here, using pancreatic cancer as a model of cachexia, the authors demonstrate that LCN2 is a critical mediator of cancer-associated anorexia and may be therapeutically targeted to improve patient outcomes.